InflaRx N.V.
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Nov 9, 2026 (14 days)
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 14, 2026 | Needham | initiate | — → Buy | — | 50% |
| Aug 7, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| May 13, 2026 | Raymond James | upgrade | Outperform → Strong Buy | — | 54% |
| May 11, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 11, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | — | 50% |
| Apr 21, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Mar 20, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Dec 30, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $6 | 44% |
| Dec 3, 2025 | Leerink Partners | downgrade | Outperform → Market Perform | $2 | 50% |
| Nov 10, 2025 | Guggenheim | maintain | Buy → Buy | $22 | 52% |
| May 29, 2025 | Oppenheimer | maintain | Outperform → Outperform | $3 | 52% |
| May 8, 2025 | Oppenheimer | initiate | — → Outperform | $6 | 52% |
| Apr 29, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $10 | 50% |
| Mar 26, 2025 | Guggenheim | maintain | Buy → Buy | $10 | 52% |
| Mar 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Mar 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Jan 16, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Dec 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Nov 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Nov 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Sep 25, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Jun 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Jun 6, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| May 9, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Mar 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $8 | 44% |
| Jan 25, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $8 | 44% |
| Nov 2, 2023 | Raymond James | maintain | Strong Buy → Strong Buy | $19 | 54% |
| Sep 12, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Aug 31, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| Aug 11, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| May 12, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $9 | 44% |
| May 12, 2023 | Raymond James | maintain | Strong Buy → Strong Buy | $21 | 54% |
| Apr 21, 2023 | HC Wainwright & Co. | maintain | — → Buy | $9 | 44% |
| Apr 6, 2023 | Raymond James | maintain | — → Strong Buy | $25 | 54% |
| Apr 5, 2023 | Guggenheim | upgrade | Neutral → Buy | $8 | 52% |
| Apr 5, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $10 | 44% |
| Apr 5, 2023 | LifeSci Capital | upgrade | Market Perform → Outperform | $0 | 57% |
| Mar 23, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $6 | 44% |
| Jan 6, 2023 | HC Wainwright & Co. | maintain | — → Buy | $6 | 44% |
| Nov 10, 2022 | Raymond James | maintain | — → Strong Buy | $8 | 54% |
| Aug 8, 2022 | HC Wainwright & Co. | maintain | — → Buy | $8 | 44% |
| May 13, 2022 | Credit Suisse | maintain | — → Underperform | $2 | — |
| May 13, 2022 | Raymond James | maintain | — → Strong Buy | $7 | 54% |
| May 13, 2022 | HC Wainwright & Co. | maintain | — → Buy | $7 | 44% |
| May 12, 2022 | SVB Leerink | maintain | — → Outperform | $4 | — |
| Mar 25, 2022 | SVB Leerink | maintain | — → Outperform | $6 | — |
| Nov 8, 2021 | Raymond James | maintain | — → Strong Buy | $15 | 54% |
| Oct 28, 2021 | Raymond James | upgrade | Outperform → Strong Buy | $14 | 54% |
| Aug 6, 2021 | Raymond James | maintain | — → Outperform | $10 | 54% |
| Aug 6, 2021 | Credit Suisse | maintain | — → Underperform | $2.5 | — |
No cross-platform signals in the last 90 days